PXD042728 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Disruption of the ALK tumor cell proteome by concurrent inhibation of ALK and SRC kinases |
Description | Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, refractory tumors with compound mutations or diverse resistance mechanisms remain an unmet clinical need. In this study, we established mouse tumor-derived cell models representing the most common EML4-ALK variants in human lung adenocarcinomas and characterized their proteomic profiles. We demonstrated that Eml4-Alk variant 3 confers a worse response to ALK inhibitors, suggesting its role in promoting resistance. In addition, proteomic analysis of brigatinib-treated cells revealed the upregulation of SRC kinase, which is frequently activated in cancer. Co-targeting of ALK and SRC showed remarkable inhibitory effects on both ALK-driven murine tumor growth and ALK-patient-derived cells. This death mechanism is attributed to the profound perturbation of the (phospho)proteomic landscape, together with a synergistic suppressive effect on the mTOR pathway. Taken together, our study identifies the inhibition of ALK and SRC cells and may offer a promising strategy to overcome resistance mechanisms and improve clinical outcomes in ALK-positive lung cancer patients. |
HostingRepository | PRIDE |
AnnounceDate | 2024-04-11 |
AnnouncementXML | Submission_2024-04-11_00:17:42.763.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Marcel Schilling |
SpeciesList | scientific name: Mus musculus (Mouse); NCBI TaxID: 10090; |
ModificationList | No PTMs are included in the dataset |
Instrument | Orbitrap Exploris 480 |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2023-06-05 06:25:22 | ID requested | |
⏵ 1 | 2024-04-11 00:17:43 | announced | |
2 | 2024-10-22 06:35:49 | announced | 2024-10-22: Updated project metadata. |
Publication List
10.1016/j.drup.2024.101081; |
Diaz-Jimenez A, Ramos M, Helm B, Chocarro S, Frey DL, Agrawal S, Somogyi K, Klingm, ü, ller U, Lu J, Sotillo R, Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. Drug Resist Updat, 74():101081(2024) [pubmed] |
Keyword List
submitter keyword: (phospho)proteomics, EML4-ALK,Precision oncology, tyrosine kinase inhibitor (TKIs), non-small cell lung cancer (NSCLC) |
Contact List
Prof. Ursula Klingmüller |
contact affiliation | German Cancer Research Center Heidelberg, Division: Systems Biology of Singal Transduction |
contact email | u.klingmueller@dkfz.de |
lab head | |
Marcel Schilling |
contact affiliation | Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg |
contact email | m.schilling@dkfz.de |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/04/PXD042728 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD042728
- Label: PRIDE project
- Name: Disruption of the ALK tumor cell proteome by concurrent inhibation of ALK and SRC kinases